Outsmarting immune suppression through GPCR innovation
Drug Target Review
JULY 18, 2025
DT-7012 retains its depletion activity even in high CCL1-concentrated environments – an essential property not shared by most competitor antibodies currently in clinical development.” Preparing for the clinic Preclinical success is just the beginning. For DT-7012, Domain is now translating its data into clinical plans.
Let's personalize your content